Skip to Main content Skip to Navigation
Journal articles

CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome

Catharina Gross 1 Céline Meyer 2 Urvashi Bhatia 1 Lidia Yshii 2 Ilka Kleffner 1 Jan Bauer 3 Anna Tröscher 3 Andreas Schulte-Mecklenbeck 1 Sebastian Herich 1 Tilman Schneider-Hohendorf 1 Henrike Plate 1 Tanja Kuhlmann 1 Markus Schwaninger 4 Wolfgang Bruck 5 Marc Pawlitzki 1 David-Axel Laplaud 6 Delphine Loussouarn 7 John Parratt 8 Michael Barnett 9 Michael Buckland 10 Todd Hardy 10 Stephen Reddel 10 Marius Ringelstein 11 Jan Dörr 12 Brigitte Wildemann 13 Markus Kraemer 11 Hans Lassmann 14 Romana Höftberger 3 Eduardo Beltrán 15 Klaus Dornmair 15 Nicholas Schwab 1 Luisa Klotz 1 Sven Meuth 1 Guillaume Martin-Blondel 16, 2 Heinz Wiendl 1 Roland Liblau 2
Abstract : Neuroinflammation is often associated with blood-brain-barrier dysfunction, which contributes to neurological tissue damage. Here, we reveal the pathophysiology of Susac syndrome (SuS), an enigmatic neuroinflammatory disease with central nervous system (CNS) endotheliopathy. By investigating immune cells from the blood, cerebrospinal fluid, and CNS of SuS patients, we demonstrate oligoclonal expansion of terminally differentiated activated cytotoxic CD8+ T cells (CTLs). Neuropathological data derived from both SuS patients and a newly-developed transgenic mouse model recapitulating the disease indicate that CTLs adhere to CNS microvessels in distinct areas and polarize granzyme B, which most likely results in the observed endothelial cell injury and microhemorrhages. Blocking T-cell adhesion by anti-α4 integrin-intervention ameliorates the disease in the preclinical model. Similarly, disease severity decreases in four SuS patients treated with natalizumab along with other therapy. Our study identifies CD8+ T-cell-mediated endotheliopathy as a key disease mechanism in SuS and highlights therapeutic opportunities. disease severity decreases in four SuS patients treated with natalizumab along with other therapy. Our study identifies CD8+ T-cell-mediated endotheliopathy as a key disease mechanism in SuS and highlights therapeutic opportunities.
Complete list of metadatas

Cited literature [87 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02448919
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Wednesday, January 22, 2020 - 3:36:19 PM
Last modification on : Wednesday, March 18, 2020 - 11:24:02 AM

File

s41467-019-13593-5.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Catharina Gross, Céline Meyer, Urvashi Bhatia, Lidia Yshii, Ilka Kleffner, et al.. CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nature Communications, Nature Publishing Group, 2019, 10 (1), pp.5779. ⟨10.1038/s41467-019-13593-5⟩. ⟨inserm-02448919⟩

Share

Metrics

Record views

44

Files downloads

99